C. L. Vogel

516 total citations
28 papers, 423 citations indexed

About

C. L. Vogel is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. L. Vogel has authored 28 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 13 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. L. Vogel's work include Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (12 papers) and HER2/EGFR in Cancer Research (6 papers). C. L. Vogel is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (12 papers) and HER2/EGFR in Cancer Research (6 papers). C. L. Vogel collaborates with scholars based in United States, Netherlands and Canada. C. L. Vogel's co-authors include Allen S. Melemed, José Iglesias, Martin E. Blackstein, Howard A. Burris, Joyce O’Shaughnessy, Barbara Klencke, Hope S. Rugo, M. Birkner, Svetislava J. Vukelja and R. Borson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

C. L. Vogel

28 papers receiving 396 citations

Peers

C. L. Vogel

ONCOL

CR

GENET

MB

PRM

John Dulos Netherlands

Stefan A. Cohen United States

Issei Matsubara Japan

Hee Jung Kwon South Korea

Balvinder Shoker United Kingdom

Sally Lane United Kingdom

E. McDermott Ireland

Yu‐zhong Duan China

Maddalena T. Tilli United States

K. Papadopoulos United States

John Dulos Netherlands

C. L. Vogel

300 ×1.1

ONCOL

35 ×0.4

CR

83 ×1.3

GENET

196 ×3.4

MB

46 ×0.8

PRM

Citations per year, relative to C. L. Vogel C. L. Vogel (= 1×) peers John Dulos

Countries citing papers authored by C. L. Vogel

Since Specialization

Citations

This map shows the geographic impact of C. L. Vogel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. L. Vogel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. L. Vogel more than expected).

Fields of papers citing papers by C. L. Vogel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. L. Vogel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. L. Vogel. The network helps show where C. L. Vogel may publish in the future.

Co-authorship network of co-authors of C. L. Vogel

This figure shows the co-authorship network connecting the top 25 collaborators of C. L. Vogel. A scholar is included among the top collaborators of C. L. Vogel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. L. Vogel. C. L. Vogel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Vogel, C. L., K. Bloom, Howard A. Burris, et al.. (2011). P1-07-02: Discordance between Central and Local Laboratory HER2 Testing from a Large HER2−Negative Population in VIRGO, a Metastatic Breast Cancer Registry.. Cancer Research. 71(24_Supplement). P1–7. 8 indexed citations

2.

Krop, Ian E., Howard A. Burris, Hope S. Rugo, et al.. (2009). Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1). Journal of Clinical Oncology. 27(15_suppl). 1003–1003. 6 indexed citations

3.

Vogel, C. L., Howard A. Burris, Steven Limentani, et al.. (2009). A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results. Journal of Clinical Oncology. 27(15_suppl). 1017–1017. 50 indexed citations

4.

Perez, Alejandra, et al.. (2005). Acupuncture for the management of hot flashes in women with early stage breast cancer treated with tamoxifen or an aromatase inhibitor: A pilot study of efficacy, safety and feasibility. Journal of Clinical Oncology. 23(16_suppl). 703–703. 5 indexed citations

5.

Vogel, C. L., et al.. (2004). Safety of zoledronic acid in patients who have previously received bisphosphonate therapy. Journal of Clinical Oncology. 22(14_suppl). 8156–8156. 1 indexed citations

6.

Vogel, C. L., John R. Mackey, & M. González Martín. (2004). The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001. Journal of Clinical Oncology. 22(14_suppl). 677–677. 6 indexed citations

7.

Vogel, C. L., John R. Mackey, & M. González Martín. (2004). The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001. Journal of Clinical Oncology. 22(14_suppl). 677–677. 3 indexed citations

8.

Blackstein, Martin E., et al.. (2002). Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial. Oncology. 62(1). 2–8. 131 indexed citations

9.

Burris, H.A., Kathy S. Albain, Francesco Greco, et al.. (1999). Phase II trial of docetaxel and Herceptin (R) as first- or second-line chemotherapy for women with metastatic breast cancer whose tumours overexpress HER2. European Journal of Cancer. 35. S322–S322. 1 indexed citations

10.

Vogel, C. L.. (1995). Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review.. PubMed. 22(2 Suppl 5). 61–5. 7 indexed citations

11.

Carpenter, J., et al.. (1986). Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial.. PubMed. 70(9). 1073–9. 6 indexed citations

12.

Brubaker, Leonard H., C. L. Vogel, Lawrence Einhorn, & Robert Birch. (1986). Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial.. PubMed. 70(2). 305–6. 10 indexed citations

13.

Klein, Leonard M., C. L. Vogel, Richard J. Johnson, et al.. (1985). Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors.. Journal of Clinical Oncology. 3(1). 121–127. 6 indexed citations

14.

Vogel, C. L.. (1981). Management of Kaposi's sarcoma. Chemotherapy I.. PubMed. 29. 82–7. 5 indexed citations

15.

Js, Thompson, et al.. (1980). Studies on levamisole--induced agranulocytosis. Blood. 56(3). 388–396. 43 indexed citations

16.

Vogel, C. L., et al.. (1980). Studies on levamisole--induced agranulocytosis. Blood. 56(3). 388–396. 47 indexed citations

17.

Vogel, C. L.. (1978). Recent trends in breast cancer treatment.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 4(2). 13–8. 1 indexed citations

18.

Vogel, C. L., et al.. (1978). Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 62(12). 2113–5. 20 indexed citations

19.

Vogel, C. L., et al.. (1974). Dopa and 5-S-cysteinyldopa in malignant melanoma in Ugandan Africans. Acta Dermato Venereologica. 54(1). 19–20. 12 indexed citations

20.

Vogel, C. L., et al.. (1972). Preliminary clinical trials of dichloromethotrexate (NSC-29630) in hepatocellular carcinoma.. PubMed. 56(2). 249–58. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact